血流导向装置治疗颅内动脉瘤:一项实用性随机对照试验
结果显示两组3个月死亡或依赖(mRS>2)无显著差异,但血流导向装置组主要疗效结局(复合终点)更优。
要点
- 对于未破裂、大型、颈内动脉动脉瘤,血流导向装置在血管造影结局上优于替代标准管理。
- 两组3个月死亡或依赖(mRS>2)发生率无统计学差异。
- 主要疗效复合终点(包括残余动脉瘤、破裂、占位效应进展、死亡或依赖)血流导向装置组更低。
临床应用与阅片要点
- 对于未破裂、大型、颈内动脉动脉瘤,血流导向装置可作为优先考虑的治疗选择之一。
- 报告时应关注随访血管造影有无残余动脉瘤、动脉瘤破裂及进展性占位效应。
- 需注意两组3个月死亡或依赖无显著差异,安全性需个体化评估。
局限性
- 开放标签设计可能引入偏倚。
- 仅纳入3个加拿大中心,外推性受限。
- 部分患者(14%)进入登记组接受血流导向装置,非随机比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Flow diversion is a recent endovascular treatment for intracranial aneurysms. We compared the safety and efficacy of flow diversion with the alternative standard management options.
MATERIALS AND METHODS: A parallel group, prerandomized, controlled, open-label pragmatic trial was conducted in 3 Canadian centers. The trial included all patients considered for flow diversion. A Web-based platform 1:1 randomly allocated patients to flow diversion or 1 of 4 alternative standard management options (coiling with/without stent placement, parent vessel occlusion, surgical clipping, or observation) as prespecified by clinical judgment. Patients ineligible for alternative standard management options were treated with flow diversion in a registry. The primary safety outcome was death or dependency (mRS > 2) at 3 months. The composite primary efficacy outcome included the core lab-determined angiographic presence of a residual aneurysm, aneurysm rupture, progressive mass effect during follow-up, or death or dependency (mRS > 2) at 3-12 months.
RESULTS: Between May 2011 and November 2020, three hundred twenty-three patients were recruited: Two hundred seventy-eight patients (86%) had treatment randomly allocated (139 to flow diversion and 139 to alternative standard management options), and 45 (14%) received flow diversion in the registry. Patients in the randomized trial frequently had unruptured (83%), large (52% ≥10 mm) carotid (64%) aneurysms. Death or dependency at 3 months occurred in 16/138 patients who underwent flow diversion and 12/137 patients receiving alternative standard management options (relative risk, 1.33; 95% CI, 0.65-2.69; P = .439). A poor primary efficacy outcome was found in 30.9% (43/139) with flow diversion and 45.6% (62/136) of patients receiving alternative standard management options, with an absolute risk difference of 14.7% (95% CI, 3.3%-26.0%; relative risk, 0.68; 95% CI, 0.50-0.92; P = .014).
CONCLUSIONS: For patients with mostly unruptured, large, anterior circulation (carotid) aneurysms, flow diversion was more effective than the alternative standard management option in terms of angiographic outcome.
引用
- Raymond, Iancu, Boisseau, et al. Flow Diversion in the Treatment of Intracranial Aneurysms: A Pragmatic Randomized Care Trial. AJNR Am J Neuroradiol. 2022. PMID: 35926886. doi:10.3174/ajnr.A7597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。